Joint development agreement signed between I-Tech and IFF

I-Tech, developer of the barnacle-repelling active antifouling ingredient, Selektope®, has entered into a collaboration agreement with IFF, a leader in bioscience and microbial control solutions, with the purpose of identifying potential benefits of combining their technologies.

Swedish bio-tech company I-Tech AB (publ) (ticker: ITECH), developers of the antifouling technology, Selektope®, has signed a joint development agreement with IFF Microbial Control, providers of SEA-NINE™ 211N, and developers of the new SEA-NINE™ ULTRA marine antifouling agent technology.

The two entities seek to explore technical opportunities by combining their respective technologies, which together can offer high performance, sustainable and regulatory compliant solutions against the wide spectrum of marine fouling species. Selektope® offers a novel approach to repel hard fouling organisms efficiently from a submerged surface, while IFF’s SEA-NINE™ platform offers efficient protection against soft fouling and long-lasting performance during the service life thanks to their new encapsulation technology. Both technologies belong to a rare set of active agents that are approved by regulatory bodies in leading nations for ship repair and new ship building.

Through the collaboration, both parties will work together to develop active ingredient compositions that would comprise a range of combinations of Selektope®, SEA-NINE™ 211N and SEA-NINE™ULTRA, together with other commonly used ingredients for marine antifoulant applications. Joint investments will include R&D activities where such will be tested in marine environments and analysed to identify potential benefits of using a combination of the technologies in antifouling systems.

Dr Markus Hoffmann, Technical Director of I-Tech AB says:

“The market demand for premium sustainable antifouling paints, that are both well-suited to specific ship trading patterns and varying activity levels, in addition to protecting against both soft and hard fouling, is increasing. This collaboration is exploring innovative solutions to meet the future demands of fouling protection. Our combined products are complementary, and the knowledge created in this project will enable our customers to offer new solutions for fouling prevention.”

David Laganella, R&D Director of IFF Microbial Control Says:

“We believe that the benefits of our combined technologies, technical expertise and R&D capabilities can go beyond performance improvements and incremental changes in formulation compositions. The results to come could open new ways for the industry to approach copper free formulations, for safer, more cost effective and more sustainable solutions for both humans and the environment.”

For more information, please contact

Markus Hoffmann, Technical Director
M: +34 064 898 16 32


Philip Chaabane, CEO
M: +46 73 910 37 08

About I-Tech AB

I-Tech is a biotechnology company that has developed the product Selektope®, an active agent that prevents barnacle attachment on submerged surfaces such as ships and boat hulls, but also other marine installations. By increasing the resistance to barnacle growth in marine paint systems (e.g. antifouling coatings), fuel and maintenance costs are reduced. I-Tech has obtained the necessary regulatory approvals for Selektope® and has several of the world's largest manufacturers of marine antifouling coatings as customers. The company's share is listed for trading on Nasdaq First North in Stockholm with Erik Penser Bank as Certified Adviser, phone: +46 (0)8 463 83 00, email:

About Selektope®

Selektope® introduces, for the first time, a pharmacological mode of action to combat barnacle settlement. By temporarily stimulating the octopamine receptor, the barnacle larvae’s swimming behaviour is activated, and the organisms are deterred from the hull. These ground-breaking discoveries enable unrivalled power at exceptionally low concentrations, yet within the limits of rigorous risk assessments. Selektope® is an organic, non-metal compound with efficacy proven at 0.1% w/w.